Previous issue | Volume 97 | ESPE2023

61st Annual ESPE (ESPE 2023)

The Hague, Netherlands
21 Sep 2023 - 23 Sep 2023

Card image cap
The 61st ESPE Annual Meeting will now be taking place in The Hague, The Netherlands

Poster Category 1

GH and IGFs

hrp0097p1-95 | GH and IGFs | ESPE2023

Clinical and laboratory characteristics in children with growth hormone deficiency (GHD) and short stature unresponsive to stimulation tests (SUS)

Dalla Bona Eva , Andrea Lanzetta Maria , Tamaro Gianluca , Faleschini Elena , Tornese Gianuca

Background: It has been previously proposed that not all children with short stature displaying an inadequate response to tests for growth hormone (GH) secretion truly suffer from GH deficiency (GHD). Instead, amongst these, solely children with an identifiable monogenic cause of GHD or an identifiable functional or anatomical anomaly in the hypothalamic-pituitary axis should be considered GHD. The remaining patients should be defined as affected by “sho...

hrp0097p1-96 | GH and IGFs | ESPE2023

Modified Insulin Stress Test for Assessment of Growth Hormone Secretion – Experience from a University Teaching Hospital

Gupta Sanjay , Dean Olivia , Mathew Verghese , Tharian Kavitha , Willingham Linda

Introduction: Insulin stress test (IST) to diagnose growth hormone (GH) deficiency is rarely used by paediatric endocrine teams in the United Kingdom, due to concerns over safety. We share our experience of undertaking modified IST in children, with regards to safety and outcomes.Methods: We adapted the protocol for insulin stress test, proposed by Galloway et al to undertake pituitary stimulation test for our c...

hrp0097p1-97 | GH and IGFs | ESPE2023

Efficacy of long-acting growth hormone preparation in children with growth hormone deficiency

Kang Eungu , Yoojin Chung Lindsey , Rhie Young-Jun , Lee Kee-Hyoung , Nam Hyo-Kyoung

Objectives: Convenience of growth hormone (GH) use can lead to good adherence and result in satisfactory treatment outcomes. The aim of this study is to compare the long-term efficacy of weekly GH with daily GH in children with GH deficiency (GHD).Methods: Clinical data of 966 GHD children (773 treated with daily GH and 193 treated with weekly GH) were obtained from the “LG Growth Study”, which is an observat...

hrp0097p1-98 | GH and IGFs | ESPE2023

Evaluation of patients with growth hormone deficiency during the transition period

Bensalah Meriem , Iabbassen Malek , Haffaf Lounes , Bouchenna Amira , Lachkhem Aicha , Yahi Abdelkader , Sellal Zoubir , Medjaher Meriem , Khadidja Ouldkablia Samia

Introduction: The transition period between childhood and adulthood in patients with growth hormone deficiency is a vulnerable period during the follow-up. Different consensuses have established follow-up and reassessment protocols for this period in order to clarify whether GHD persists. The benefits of maintaining treatment during this period are widely documented on the metabolic, vascular, bone and in terms of quality of life and well-being.<p class="a...

hrp0097p1-99 | GH and IGFs | ESPE2023

Clinicians’ perceptions on ease of use and usefulness of Aluetta® Smartdot™ and comprehensive digital health ecosystem in Italy to support patients receiving r-hGH treatment

Felicia Faienza Maria , Vergani Edoardo , Di Mase Raffaella , Frasca Francesco , Giavoli Claudia , Klain Antonella , Laura Iezzi Maria , Aversa Antonio , Koledova Ekaterina , Rivera Romero Octavio

Background: Aluetta® Smartdot™ (Merck Healthcare KGaA, Darmstadt, Germany) is first of its kind digitally connected smart injection pen device for recombinant-human growth hormone (r-hGH) administration. Aluetta® pen with Smartdot™ knob attachment integrated with Growzen™ digital ecosystem enables healthcare professionals (HCPs) to remotely monitor adherence and achieve optimal clinical outcomes for patients....

hrp0097p1-100 | GH and IGFs | ESPE2023

Exploring healthcare professionals’ attitudes towards digitalization and the perceived usefulness and ease of use of digital solutions in patients receiving growth hormone therapy: Results of a Korean participatory study

Wook Chae Hyun , Rivera Romero Octavio , Kun Cheon Chong , Sang Lee Hae , Kim Jihyun , Eun Moon Jung , Koledova Ekaterina , Sil Oh Eun , Yang Yoo-Jin , Rhie Young-Jun

Background: Aluetta® Smartdot™ (Merck Healthcare KGaA, Darmstadt, Germany) is a novel injection device for administering recombinant-human growth hormone (r-hGH), integrated with a smart knob attachment for data transmission that combines ease of use with advanced capabilities. Integration with Growzen™ digital ecosystem empowers healthcare professionals (HCPs) with remote monitoring of patient adherence, thereby promoting optimal cl...

hrp0097p1-101 | GH and IGFs | ESPE2023

Withdrawing growth hormone treatment at mid-puberty in idiopathic isolated growth hormone deficiency: baseline characteristics in patient-preference design study

Vliegenthart Joeri , Wit J.M. , Bakker B. , Boot A.M. , de Bruin C. , Finken M.J.J. , van der Heyden J.C. , Houdijk E.C.A.M. , van der Kamp H.J. , van Mil E.G.A.H. , Reedijk A.M.J. , Sas T.C.J. , Schott D.A. , van Setten P. , Straetemans S. , van Tellingen V. , Touwslager R.N.H. , van Trotsenburg A.S.P , Voorhoeve P.G. , van der Kaay D.C.M.

Background: The majority of children diagnosed with idiopathic isolated growth hormone deficiency (IIGHD) show a normal growth hormone (GH) secretion (assessed by GH stimulation tests) when retested at near adult height (NAH). It appears plausible that if normal stimulated GH secretion is observed in mid-puberty, continuing recombinant human GH (rhGH) treatment may only have a minor effect on NAH. The effect on NAH has never been investigated in a prospective ...

hrp0097p1-102 | GH and IGFs | ESPE2023

Assessment of clinical pediatric perception of short stature in childhood and challenges to treat with Growth Hormone in Brazil: A exploratory evaluation of a developing country daily practice.

Barquero Paula , Aranha Pedro , Souza Leonardo , Careli Guilherme , Veçoso Marcos , Freire Daniel , Sato Cleber

Background: Concerns about a child's growth are one of the most common topics parents express during pediatric visits and are a leading cause for referral to a pediatric endocrinologist. For the general pediatric, when short stature is diagnosed, its clinical management remains a challenge.Objective: The aim of the study was to approach and understand the perception from the general pediatrician about short stature,...

hrp0097p1-103 | GH and IGFs | ESPE2023

Assessing the treatment burden and Quality of Life of children receiving daily recombinant Growth Hormone treatment in Greece

Christoforidis Athanasios , Galli-Tsinopoulou Assimina , Karachaliou Fotini-Eleni , Chrysis Dionisios , Kanaka – Gantenbein Christina , Skiadas Ioannis , Zisimopoulou Oresteia , Poimenidou Apostolia , Windisch Manfred , Sofiaki Nikoletta , Baxevanidi Evangelia , Evelien Gevers

Background: Pediatric growth hormone deficiency (pGHD) is associated with growth attenuation/deceleration, short stature, delayed bone maturation, and metabolic defects. Daily recombinant human growth hormone (rhGH) treatment promotes linear growth and increases growth rate; however, it may present a substantial burden for patients and caregivers. This may lead to low adherence, limiting the clinical effect of treatment. This study assesses the health-related ...

hrp0097p1-104 | GH and IGFs | ESPE2023

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a French participatory study

Rivera-Romero Octavio , Perge Kevin , Cochet Solenn , Trouvin Marie-Agathe , Koledova Ekaterina

Background: Treatment of growth hormone deficiency (GHD) requires daily injections over many years. Connected digital health devices can facilitate GH treatment by automating the injection process, which reduces anxiety, and collecting injection data in real-time so that accurate adherence information is available to healthcare professionals (HCPs). In developing new digital health solutions, HCP perspectives should be considered.<strong...

hrp0097p1-105 | GH and IGFs | ESPE2023

Effects of Growth Hormone Therapy on Glucose Metabolism in Children and Adolescents: 1-year follow-up results

Derya Kardelen Aslı , Kandemir Tuğçe , Demirel Özge , Tercan Ummahan , Yıldız Melek , Poyrazoğlu Şükran , Baş Firdevs , Darendeliler Feyza , Marja Ojaniemi

Introduction: It is thought that long-term growth hormone (GH) treatment may impair hepatic glucose production and insulin-dependent glucose utilization, and therefore it is attributed that GH may adversely affect glucose metabolism.Objective: In our study, we aimed to examine the effects of GH treatment on insulin sensitivity and glucose metabolism in patients with GH deficiency after 1-year of treatment.<p class="a...

hrp0097p1-106 | GH and IGFs | ESPE2023

Growth Hormone (GH) Therapy in Children with short stature: A cross-sectional study of indication and treatment outcomes- 12-year single center experience

Al Jneibi Sara , Hammouri Marwa , Taha Fatima , Allami Zahraa , Weber Stefan , AlJubeh Jamal , Al Remeithi Sareea

Background: GH deficiency remains the main indication for GH therapy in children. GH therapy has subsequently been approved in the USA and Europe for other conditions resulting in short stature, including Turner Syndrome, being born small for gestational age with failure to attain normal growth, Prader-Willi Syndrome, chronic renal insufficiency, short stature homeobox-containing gene deficiency, and in the USA exclusively Noonan Syndrome and idiopathic short ...

hrp0097p1-107 | GH and IGFs | ESPE2023

The Growth Predictive Value of (IGF1/Growth Hormone Peak) Ratio in Children with Idiopathic Short Stature (ISS)

Soliman Ashraf , Alyafei Fawzia , Alaaraj Nada , Hamed Noor , Ahmed Shayma

Introduction: Stimulated GH peak values have been shown to correlate well with nocturnal GH peak values and with nocturnal mean GH values. In addition, the expression level of serum IGF-1 in ISS has been shown to be significantly lower than that in normal children despite their normal GH peak response to provocation. GH stimulates the production of IGF1; however, their metabolic effects are different. GH has lipolytic and anti-insulin actions while IGF1 has in...

hrp0097p1-108 | GH and IGFs | ESPE2023

A challenging case of Pituitary Gigantism

Chandwani Manju , Subbarayan Anbezhil , Levy Miles , Korbontis Marta

A 4.9-year-old girl presented with a 6-month history of excessive body odour and suspected breast development. Family history was significant for presence of Lynch syndrome in both her father and paternal grandmother. At presentation, she was pre-pubertal but tall for her age. Her height was 124 cm (SDS 3.5), and weight was 27.1 kg (SDS 2.69). Her height velocity was accelerated at 15 cm/year and bone age was advanced at 7 years. Investigations revealed an elevated IGF-1 (500 ...

hrp0097p1-288 | GH and IGFs | ESPE2023

The Growzen™ buddy smartphone application shows positive findings on adherence in Argentinian patients receiving growth hormone therapy for growth disorders

van Dommelen Paula , Arnaud Lilian , Assefi Aria , Lourdes Crespo Maria , Koledova Ekaterina

Background: Digital health solutions, such as the Growzen™ buddy smartphone application (app), can facilitate adherence to recombinant human growth hormone (r-hGH) treatment for patients with growth disorders. The app alerts patients when it’s time for an injection and allows patients and their caregivers to self-monitor growth, to build a routine and improve adherence. The app also contains educational resources to empower patients to be active in...

hrp0097p1-289 | GH and IGFs | ESPE2023

Long-term effectiveness and safety of growth hormone therapy in Japanese children with short stature due to Noonan syndrome (NS): real-world data

Muroya Koji , Kawai Masanobu , Yamagishi Hiroyuki , Endo Takaaki , Pietropoli Alberto , Horikawa Reiko

Norditropin® was approved for children with short stature due to NS in Japan in 2017. The aim of this post-marketing surveillance study was to evaluate long-term safety and effectiveness of Norditropin® for the approved indication. This real-world non-interventional study (NCT03435627) was conducted February 2018–January 2022. Seventy patients enrolled: 35 received Norditropin® after study initiation (new patients); 35 were previously ra...

hrp0097p1-290 | GH and IGFs | ESPE2023

Optimal injection device settings to achieve high adherence to growth hormone treatment in patients with growth disorders

van Dommelen Paula , Arnaud Lilian , Zucchiatti Chantal , Koledova Ekaterina

Background: Treatment for growth disorders requires daily injections of recombinant human growth hormone (r-hGH) over multiple years, and automated devices may help in this regard. The ability to adjust injection device settings, which are pre-set as default unless changed by healthcare professionals, may improve patient comfort and needle anxiety and thereby improve adherence.Aim: To study the association between inject...

hrp0097p1-291 | GH and IGFs | ESPE2023

Adult heights of the cases whose GH treatment was discontinued at early retesting reached their target heights

Vuralli Dogus , Ozon Alev , Gonc Nazli

Background: It has been reported that 25–75% of patients with diagnosis of growth hormone deficiency (GHD) may show normal growth hormone (GH) responses in repeated stimulation tests after completion of treatment. Retests are typically conducted following completion of growth phase. In a small number of studies retests are conducted during early stages of GH therapy. Accuracy of early retesting to exclude GHD can be evaluated by adult heights of those wh...

hrp0097p1-292 | GH and IGFs | ESPE2023

Clinical predictors of good/poor response to growth hormone treatment (GHT) in children with idiopathic short stature (ISS)

Dauber Andrew , Phillip Moshe , Ferran Jean-Marc , Kelepouris Nicky , Nedjatian Navid , Helene Olsen Anne , Jorge Alexander

Children with ISS vary in their response to GHT. We conducted a post hoc analysis to identify clinical characteristics associated with very good or poor response during year 1 of GHT in a subset of 1550 GH naïve children with ISS from NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905). We included patients aged 3–11 years (males) or 3–10 years (females) at treatment start, prepubertal throughout year 1 of treatment, with height SDS...

hrp0097p1-293 | GH and IGFs | ESPE2023

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a UK participatory study

Rivera-Romero Octavio , R Kapoor Ritika , Mathew Verghese , Tollerfield Sally , Shah Pratik , Banerjee Indraneel , Koledova Ekaterina

Background: Long-term treatment with recombinant human growth hormone (r-hGH) is often challenging for children and adolescents, their caregivers and healthcare professionals (HCPs), as treatment requires daily injections over several years. Connected digital health devices facilitate this by automating the injection process to improve comfort, reduce anxiety and collect GH treatment data so that accurate adherence information is available to HCPs in real-time...

hrp0097p1-294 | GH and IGFs | ESPE2023

A novel variant of IGF1R in a Chinese family with short stature and efficacy of recombinant human growth hormone therapy

Lu Huifei

Introduction: Insulin-like growth factor 1 receptor (IGF1R) mutations lead to systemic disturbances in growth due to widespread IGF1R expression throughout the body. IGF1R is expressed by innate and adaptive immune cells, facilitating their development and exerting immunomodulatory roles in the periphery.Case Report: We detected a novel heterozygous variant c.664 C > T (NM_000875) of IGF1R in a Chinese family with sho...

hrp0097p1-295 | GH and IGFs | ESPE2023

Sex steroid priming decreases the frequency of divergent results between spontaneous and stimulated GH tests

Lennartsson Otto , Nilsson Ola , Lodefalk Maria

Introduction: The diagnosis of growth hormone (GH) deficiency (GHD) is complicated by the low specificity of GH testing, especially in children before and during early pubertal stages. Sex steroid priming reduces false positive results in pre- and early pubertal children. However, only a small number of studies have assessed its efficacy in improving the diagnostic accuracy of GHD investigations.Aim: To evaluate the effe...

hrp0097p1-296 | GH and IGFs | ESPE2023

The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys

Zhang Ying , Chen Ruimin

Objective: In boys during puberty who were undergoing recombinant human growth hormone (rhGH) treatment, we compared the therapeutic efficacy and any adverse reactions, of co-therapy with letrozole/gonadotropin releasing hormone analog (GnRHa).Methods: Fifty-six pubertal growth hormone deficiency (GHD) boys were studied, they were treated with the combination of letrozole and rhGH (letrozole group) or GnRHa and rhGH (GnR...

hrp0097p1-297 | GH and IGFs | ESPE2023

Evening or morning growth hormone treatment?

Levstein Levstein Aglaya , Sharkia Mohamad , Shimshi-Barash Maya , Hochberg Ze'ev , Pillar Giora , German Alina

Context: Physiological growth hormone is secreted during the slow-wave sleep. Traditionally, growth hormone (GH) therapy is given in daily GH injections before sleep. This schedule better imitates the physiological diurnal variation of GH secretion and action. Late-night daily injections have been claimed to be associated with sleep disturbances and insomnia, yet there is no hard evidence supporting this contention. Morning and evening GH injections produce co...

hrp0097p1-298 | GH and IGFs | ESPE2023

Quality of life at adult height in adolescents and young adults treated by GH

González Briceño Laura , Magali Viaud , Beltrand Jacques , Flechtner Isabelle , Dassa Yamina , Samara-Boustani Dinane , Thalassinos Caroline , Busiah Kanetee , Pinto Graziella , Jaquet Delphine , Polak Michel

Background: short stature can lead to emotional and social stress in children and adolescents. We previously demonstrated in a cohort of 74 children that a one-year growth hormone treatment (GHT) is associated with a significant improvement of quality of life (QoL) especially on emotional and social scales, both in general (PedsQL 4.0) and height-specific (QoLiSSY) questionnaires. Whether this improvement is sustained until adult height remains to be documente...

hrp0097p1-299 | GH and IGFs | ESPE2023

Real-world adherence to growth hormone treatment and catch-up growth in children with growth disorders in France: An interim analysis from the SCOPE study

Polak Michel , Bouhours-Nouet Natacha , Tauber Maithé , van Dommelen Paula , Khebbeb Sarah , Castello-Bridoux Claire , De Buyst Valerie , Koledova Ekaterina , Linglart Agnès

Background: The SCOPE French retrospective study follows children affected with growth hormone (GH) disorders treated with recombinant human GH (r-hGH) therapy via the easypod® connected injection device for up to 5 years.Aim: To show the results from an interim analysis of the SCOPE study analysing adherence to r-hGH therapy in a real-world setting and its effect on catch-up growth.Met...

hrp0097p1-300 | GH and IGFs | ESPE2023

Assessment of the rhGH treatment compliance in children with growth hormone deficiency.

Scheuring Dorian , Walczak Mieczysław , Nowak Katarzyna , Dragan Wojciech , Starzyk Jerzy , Wędrychowicz Anna , Kapusta Alicja , Bossowski Artur , Sawicka Beata , Gawlik Aneta , Błaszczyk Ewa , Gieburowska Joanna , Beń-Skowronek Iwona , Trwoga Aleksandra , Sokół Martyna , Kołtowska-Häggström Maria , Kolasa-Kicińska Marzena , Łupińska Anna , Stawerska Renata , Lewiński Andrzej , Dudek Adam , Mazur Artur , Zachurzok Agnieszka , Mierzwa Magdalena , Wikiera Beata , Pyrżak Beata , Witkowska-Sędek Ewelina , Witkowska-Krawczak Ewa , Szewczak-Matan Bogumiła , Kędzia Andrzej , Moszczyńska Elżbieta , Kot Karolina , Birkholz-Walerzak Dorota , Myśliwiec Małgorzata , Petriczko Elżbieta

Aim: To identify factors affecting compliance to treatment with recombinant growth hormone (rhGH) in children with growth hormone deficiency (GHD).Study population and Methods: The following data were collected during standard visits in 8 endocrine clinics in Poland: medical history, auxological measurements, laboratory tests and the numbers of empty and full rhGH ampoules dispensed and returned by the patients. The obse...

hrp0097p1-301 | GH and IGFs | ESPE2023

Outcome of growth hormone treatment in growth hormone deficient children over the course of 3 years in Notre Dames Des Secours-University Medical Center Byblos-Lebanon-single center experience

Nicolas Georges , El Kortbaoui Anthony

Key words: Descriptive study, short stature, Growth Hormone deficiency, Growth Hormone analogue, Lebanon, NDS-UMC, Byblos, single center experience.Background: There is a lack of national data concerning growth hormone deficiency treatment in Lebanon. The aim of this study is to describe the height gained under growth hormone therapy of 39 patients diagnosed with growth hormone deficiency (GHD).<st...

hrp0097p1-302 | GH and IGFs | ESPE2023

Influencing Factors on Selection of Initial Treatment Dose in Children Diagnosed with Isolated Growth Hormone Deficiency

Mert Erbaş İbrahim , Uyar Nilüfer , Nalbantoğlu Özlem , Özkan Behzat

Background: Although it has been recommended to start treatment in the range of 22-35 µg/kg/day in growth hormone (GH) deficiency, individualized dose selection is more preferred for those patients instead of a fixed dose. However, there is no consensus as to which dose should be started for which patient. In this study, we aimed to reveal the factors that affect the clinicians' preferences in the selection of the starting dose of GH treatment.<...

hrp0097p1-303 | GH and IGFs | ESPE2023

Further analyses on the role of IGF-I in the diagnosis of GH deficiency (GHD) in children

Lussu Anna , Incandela Valeria , Guzzetti Chiara , Ibba Anastasia , Casula Letizia , Loche Sandro

Background: The diagnosis of GHD in children is based on auxological, biochemical, neuro-radiological, and genetic tests. Biochemical tests include evaluation of stimulated GH secretion and baseline IGF-1 determination. Although IGF-1 is the most reliable indicator of GH action, its value should always be interpreted in conjunction with other clinical and biochemical parameters. Since IGF-1 has good specificity (about 90%), but low sensitivity (about 70%), nor...

hrp0097p1-304 | GH and IGFs | ESPE2023

Prevalence and predictors for growth hormone deficiency in children born small for gestational age with short stature

Cvetković Dimitrije , Milenković Tatjana , Todorović Slađana , Mitrović Katarina , Vuković Rade , Panić Zarić Sanja , Čehić Maja

Introduction: Small for gestational age (SGA) is a common condition affecting around 10% of all newborns, and it is associated with an increased risk of short stature and other health problems later in life. Growth hormone deficiency (GHD) is a well-known cause of growth failure in children, and it is estimated to affect approximately 1 in 4.000-10.000 children. However, the prevalence of GHD in SGA children with short stature is not well established. Early de...

hrp0097p1-305 | GH and IGFs | ESPE2023

A rare case of microduplication 5q35.2-q35.3, also known as anti-Sotos syndrome, in a female patient.

Bianco Carlo , Montafia Ilaria , Pagliero Federica , Aquisti Giulia , Petri Antonella , Bellone Simonetta , Rabbone Ivana , Prodam Flavia , Partenope Cristina

V.C. was referred to our Centre for short stature. The mid-parental target height was 153 cm (-1,6 SDS). Her mother had one spontaneous abortion and displayed mild short stature (151,5 cm). Her father had Arnold Chiari syndrome type 1 and was 165,9 cm tall. V.C. was delivered at term after in-vitro-fertilization pregnancy with intrauterine growth retardation (IUGR) from gestational week 21. Birth weight was 2160 g (SGA, SDS -3,17); length was 45 cm (SDS -2,92); head circumfere...

hrp0097p1-489 | GH and IGFs | ESPE2023

Effects of GH therapy in patients with GHD (Growth Hormone Deficiency) on glucose homeostasis: results of a 10-years follow-up

Vasaturo Sara , Illiano Sara , Mirra Rita , Lorello Paola , Apuzzo Diletta , Di Mase Raffaella , Capalbo Donatella , Salerno Mariacarolina

Objectives: Among adverse effects of GH, a particular attention should be given to glucose homeostasis. The aim of the study was evaluate the effect of GH therapy on glucose homeostasis in children with GHD after 10 years of treatment.Methods: 30 patients (8 M/22 F, age 7.00 &pm; 2.61 years) with GHD at diagnosis and 30 healthy children comparable to patients for age, sex and BMI were enrolled. Glucose, insulin, HOMA-IR ...

hrp0097p1-490 | GH and IGFs | ESPE2023

Phenotype and genotype of children with biallelic GHRHR gene mutations: a Belgian case series

Van de Velde Simone , Boros Emese , Brunelle Chloë , Beckers Dominique , De Schepper Jean , Thomas Muriel , Heinrichs Claudine , Brachet Cécile

Background: Children with biallelic GHRHR gene pathogenic variants share a phenotype of growth failure starting in infancy and resulting in a proportionate short stature and bone age delay due to a complete isolated growth hormone (GH) deficiency. The genotype ranges from rare promotor mutations to the more frequent splicing mutations, some genotypes being specific to certain geographic areas. Diagnosis is mainly made around the age of 7 years and more often i...

hrp0097p1-491 | GH and IGFs | ESPE2023

Priming with sex steroids increases the specificity of GH tests in the diagnosis of “True” isolated growth hormone deficiency

Vuralli Dogus , Ozon Alev , Gonc Nazli

Background and Aim: Priming with sex steroids before growth hormone (GH) stimulation tests is considered to increase the specificity of the GH stimulation tests, however, its use in the diagnosis of growth hormone deficiency (GHD) is still controversial. Purpose of this study is to analyze efficacy of sex steroid priming in the diagnosis of GHD.Methods: The study comprised 115 peripubertal boys who were diagnosed with is...

hrp0097p1-492 | GH and IGFs | ESPE2023

GH stimulation testing: is it time to change the paradigm?

Smuel Keren , Lazar Liora , Yackobovitch-Gavan Michal , Tirosh Liron , Phillip Moshe , Oron Tal , Sarah Flanagan , Jayne Houghton

Background: The efficacy of growth hormone (GH) treatment in short, healthy children diagnosed with growth hormone deficiency (GHD) or those meeting the criteria of idiopathic short stature (ISS) suggest that an overlap exists between these two conditions. Although flawed and inconsistent, growth hormone stimulation tests (GHST) are the key diagnostic tool differentiating between GHD and ISS affecting clinical decisions such as treatment eligibility and dose.<...

hrp0097p1-493 | GH and IGFs | ESPE2023

Use of aromatase inhibitors in short children and adolescents to optimize final height: A current practice survey

Zepeda Diego , Mericq Veronica

Introduction: Management of pediatric patients with short stature and poor adult height prognosis it’s challenging and effectiveness of treatment with growth-promoting agents is controversial when linear growth is ending. Aromatase inhibitors (AI) have become a therapeutic option as they promote slowdown of bone maturation and increase final height, but yet is a non-approved indication.Aim: To conduct a survey abou...

hrp0097p1-494 | GH and IGFs | ESPE2023

Comparison of insulin tolerance test and arginine test in the diagnosis of growth hormone deficiency in children

Kang Eungu , Jin Kim Yu , Nam Hyo-Kyoung , Lee Kee-Hyoung , Rhie Young-Jun

Background: The diagnosis of growth hormone deficiency (GHD) requires the subnormal responses to two provocation tests. This study evaluated the value of the growth hormone provocation test using arginine and insulin-induced hypoglycemia to diagnose growth hormone deficiency (GHD).Method: This study included 294 children with short stature (136 girls and 158 boys) who underwent a growth hormone provocation test using the...

hrp0097p1-495 | GH and IGFs | ESPE2023

Difficulties in interpreting insulin-like growth factor 1 (IGF-1) levels in short stature children born small for gestational age (SGA) treated with recombinant human growth hormone (rhGH) based on data from six clinical centres in Poland.

Glińska Marta , Walczak Mieczysław , Wikiera Beata , Pyrżak Beata , Majcher Anna , Paluchowska Monika , Gawlik Aneta , Antosz Aleksandra , Kusz Marcin , Bossowski Artur , Stożek Karolina , Wędrychowicz Anna , Starzyk Jerzy , Petriczko Elżbieta

Introduction: The assessment of IGF-1 concentrations is one of the parameters used for evaluating response to rhGH treatment. An increase in IGF-1 concentration positively correlates with growth improvement. The IGF-1 concentrations significantly above the reference range may increase total the risk of possible side effects. High IGF-1 concentration is one of the reasons for rhGH dose reduction which affects the response to treatment.<st...

hrp0097p1-496 | GH and IGFs | ESPE2023

Comparative Efficacy of Growth Hormone treatment on children with Idiopathic Growth Hormone Deficiency (and Idiopathic Short Stature (A 12year Tertiary Center Experience

Ahmed Fatima , Hammouri Marwa , Allami Zahraa , Al Jneibi Sara , Al Jubeh Jamal , Weber Stefan , Al Remeithi Sareea

Short stature is one of the most common concerns presented to pediatric endocrinologists. ISS describes a heterogeneous group of children with a height of more than 2 SD score (SDS) below the corresponding mean height for a given age, sex, and population group without underlying aetiology. The primary objectives of GH treatment are acceleration of growth velocity to promote normalization of stature during childhood and attainment of normal FAH.Ob...

hrp0097p1-497 | GH and IGFs | ESPE2023

First-year response to growth hormone (rGH) treatment and assessment of iGRO software for the prediction of growth velocity.

Kosteria Ioanna , Atnanasouli Fani , Dikaiakou Eirini , Leka-Emiris Sofia , Vlachopapadopoulou Elpis-Athina

Objectives: Response to rGH during the first year of treatment is considered indicative of its effectiveness for the improvement of final height. The iGRO software assesses the response to rGH in children with idiopathic growth hormone deficiency (IGHD) or small for gestational age (SGA) based on age, gender, gestational age, birthweight, rGH dose, maximal GH during stimulation tests, as well as weight and height measurements on follow-up visits. The aim was t...

hrp0097p1-498 | GH and IGFs | ESPE2023

The relationship between body mass index and therapeutic effect in children with idiopathic growth hormone deficiency

Sang Lee Hae , Suk Shim Young , Soon Hwang Jin , Sub Lim Jung

Purpose: The aim of this study is to investigate the influence of body mass index (BMI) on therapeutic effect in prepubertal children with idiopathic growth hormone deficiency (IGHD).Methods: We conducted a retrospective study by chart review in a single center. A total of 138 patients (male n=90, female n=48) with idiopathic growth hormone deficiency who were was treated growth hormone for at least 2 y...

hrp0097p1-499 | GH and IGFs | ESPE2023

Growth characteristics and final height in survivors of childhood medulloblastoma.

Stern Eve , Ben Ami Michal , Caspi Shani , Lurye Michal , Abebe-Campino Gadi , Yalon Michal , Modan-Moses Dalit

Background and aim: Medulloblastoma is a highly malignant childhood brain tumor, requiring treatment with high dose cranio-spinal irradiation and aggressive chemotherapy. Survivors of are at high risk for multiple endocrine deficiencies, including growth retardation and growth hormone (GH) deficiency. Previous studies reported decreased final adult height in survivors of childhood medulloblastoma, with height standard deviation score (SDS) ranging from -1.9 to...

hrp0097p1-500 | GH and IGFs | ESPE2023

Factors influencing response to growth hormone therapy in patients with growth hormone deficiency

Nguyen Thi Hang , Bui Phuong Thao , Nguyen Ngoc Khanh , Can Thi Bich Ngoc , Do Thi Thanh Mai , Nguyen Thu Ha , Nguyen Trong Thanh , Vu Chi Dung

Keywords: recombinant human growth hormone (rhGH), growth hormone deficiency (GHD), short statureBackground: Recombinant growth hormone is used for the treatment of growth hormone deficiency. In children treated early, catch-up growth is excellent, with a normal final height. A final height gain of 30 cm can be expected on average. However, it has long been recognized that there is variability in the magnitude of individ...

hrp0097p1-501 | GH and IGFs | ESPE2023

The Predictive Value of using IGF1/Growth Hormone Peak Ratio on growth parameters in Children with Growth Hormone Deficiency (GHD) before and after GH treatment.

Soliman Ashraf , Alyafei Fawzia , Alaaraj Nada , Hamed Noor , Ahmed Shayma , Elsiddig Sohair , Eldarsy Nagwa

Introduction: GH stimulates the production of IGF1; however, their metabolic effects are different. GH has lipolytic and anti-insulin actions while IGF1 has insulin-like actions.Objectives: To investigate the value of using the IGF1/GH peak ratio in relation to the anthropometric data of children with growth hormone deficiency (GHD) before and after a year of GH therapy.Patients and Methods...

hrp0097p1-502 | GH and IGFs | ESPE2023

Integration of Nurse-Led Virtual Reviews with Growth Hormone Device-Linked Adherence: a mixed methods, feasibility study

Stokes Helen , Jones Julie , Worth Chris , Nicholson Jaqueline , Fullwood Catherine , Banerjee Indraneel

Introduction: Easypod-connect™ for childhood growth disorders is a unique connected system that enables the transmission of injection adherence information for recombinant human growth hormone (r-hGH). Although this system has the potential to facilitate greater adherence, observational studies have shown declining adherence over prolonged periods when used without additional support. Supplemental nurse practitioner support has been envisaged but not inv...

hrp0097p1-503 | GH and IGFs | ESPE2023

Risk factors and best predictor of Osteopenia in preterm Neonates: single center experience

Khater Doaa , Saleem Abdulbasset , Abd ELhamid Ihab , Rezk Noha , Abdelmeguid Yasmine

Background: Osteopenia of prematurity (OOP) is serious but common concerns for parents of premature babies. Reduced bone mineralization results in OOP, or low bone density. The incidence of OOP has increased as a result of medical advancements that have allowed more very low birth weight (VLBW) infants to survive. It is inversely proportional to the intrauterine gestational age (GA).Objective: to study the risk factors a...

hrp0097p1-504 | GH and IGFs | ESPE2023

The pattern of growth in a girl with short stature and duplication at 5q35.2q35.3 encompassing NSD1

Banaszak-Ziemska Magdalena , Niedziela Marek

Introduction: Characteristic features in patients with a duplication at 5q35.2q35.3 encompassing NSD1 are short stature, microcephaly, mild developmental delay, behavioural problems, digital anomalies and defects of internal organs. The above-mentioned features are reversed to Sotos syndrome phenotype, which is associated with a microdeletion in the same chromosomal region. In the literature, 41 patients were reported so far.Case...